Associated Papers
Langerhans Cell Histiocytosis in Cardiofaciocutaneous Syndrome.
Keehan L et al.
American Journal of Medical Genetics. Part A, 2026
A scalable approach to resolving variants of uncertain significance.
Tejura M et al.
Biorxiv : the Preprint Server for Biology, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.
Menzer C et al.
European Journal of Cancer (oxford, England : 1990), 2025
Evaluating Liquid Biopsy for Circulating Tumor DNA (ctDNA) Detection as a Complementary Diagnostic Tool in Thyroid Cancer Among Ecuadorian Women.
Cadena-Ullauri S et al.
International Journal of Molecular Sciences, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice.
Parisi C et al.
Cancer, 2025
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
Multicenter In-House Evaluation of an Amplicon-Based Next-Generation Sequencing Panel for Comprehensive Molecular Profiling.
Jantus-Lewintre E et al.
Molecular Diagnosis & Therapy, 2025
Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.
Condoiu C et al.
Biomedicines, 2025
Synchronous Pulmonary Langerhans Cell Histiocytosis and Multiple Cutaneous Reticulohistiocytomas With a Common BRAF- V600E/D Mutation Driver.
Parra O et al.
The American Journal of Dermatopathology, 2025
Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.
Afsar S et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2025
VarMeter2: An enhanced structure-based method for predicting pathogenic missense variants through Mahalanobis distance.
Ohno S et al.
Computational and Structural Biotechnology Journal, 2025
Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan.
Hida T et al.
Cancer Medicine, 2024
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.
Li H et al.
Npj Precision Oncology, 2024
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal location.
Küçükosmanoglu A et al.
Molecular Oncology, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Noonan syndrome and Noonan-like syndrome with loose anagen hair: rare phenotypes may emerge during follow-up.
Liu Z et al.
Translational Pediatrics, 2024
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.
Sementsov M et al.
Embo Molecular Medicine, 2024
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape.
Planchard D et al.
Npj Precision Oncology, 2024
BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer.
Grillo F et al.
Histopathology, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways.
Wang X et al.
American Journal of Human Genetics, 2024
DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis.
Dragomir M et al.
Cancers, 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.
Castellani G et al.
Cancers, 2023
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D et al.
Neuro-oncology, 2023
Cutaneous Melanoma and Glioblastoma Multiforme Association-Case Presentation and Literature Review.
Orzan OA et al.
Diagnostics (basel, Switzerland), 2023
Electrochemical biosensors for analysis of DNA point mutations in cancer research.
Ondraskova K et al.
Analytical and Bioanalytical Chemistry, 2023
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.
Kim SJ et al.
Cancer Research and Treatment, 2023
Decoding molecular programs in melanoma brain metastases.
Radke J et al.
Nature Communications, 2022
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Girod M et al.
Jco Precision Oncology, 2022
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations.
Wei XW et al.
Jto Clinical and Research Reports, 2022
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
The earliest events in BRAF-mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways.
Bleijenberg AG et al.
The Journal of Pathology, 2022
Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C et al.
Current Treatment Options in Oncology, 2022
Binding of the B-Raf Inhibitors Dabrafenib and Vemurafenib to Human Serum Albumin: A Biophysical and Molecular Simulation Study.
Russi M et al.
Molecular Pharmaceutics, 2022
Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K et al.
Journal of Cutaneous Pathology, 2022
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation.
Wang M et al.
Journal for Immunotherapy of Cancer, 2022
Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.
Tan J et al.
Bmc Medical Genomics, 2022
Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options.
Brouwer NJ et al.
Progress in Retinal and Eye Research, 2022
Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J et al.
Plos One, 2022
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q et al.
Frontiers in Bioengineering and Biotechnology, 2022